Aconine

Research use only, not for human use.

Aconine possesses gastric anaesthetic props.

Aconine is the febrifuge. Aconine possesses gastric anaesthetic props.

Treatment with Aconine significantly inhibits the RANKL-induced transcriptional activity of NF-κB in a dose-dependent manner. Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing the activation of NF-κB and NFATc1 and the expression of the cell-cell fusion molecule DC-STAMP. Aconine (0.125, 0.25 μM) does not affect the viability of RAW264.7 cells, but dose-dependently inhibits RANKL-induced osteoclast formation and bone resorptive activity. Aconine dose-dependently inhibits the RANKL-induced activation of NF-κB and NFATc1 in RAW264.7 cells, and subsequently reduces the expression of osteoclast-specific genes (c-Src, β3-Integrin, cathepsin K and MMP-9) and the expression of dendritic cell-specific transmembrane protein (DC-STAMP), which plays an important role in cell-cell fusion.

——

Jesaconine

Others

Other Targets

Others

Others-Field

——

509-20-6

499.6

C25H41NO9

>98% (HPLC)

DMSO : ≥ 125 mg/mL; 250.21 mM

CCN1CC2(C(CC(C34C2C(C(C31)C5(C6C4CC(C6O)(C(C5O)OC)O)O)OC)OC)O)COC

——

(-20℃)

With Ice Pack

≥ 2 years